5 Key Takeaways

• 1

  Vamikibart, an anti–interleukin-6 monoclonal antibody, shows early safety in treating noninfectious uveitic macular edema.

• 2

  The phase 1 DOVETAIL trial reported no serious drug-related adverse events or sustained intraocular pressure increases with vamikibart.

• 3

  More than 80% of participants achieved complete resolution of intraretinal fluid by week 12, with improvements maintained at study end.

• 4

  Corticosteroids, the standard treatment, have limitations including cataract formation and elevated intraocular pressure.

• 5

  Ongoing phase 3 trials, MEERKAT and SANDCAT, will further assess the safety and efficacy of vamikibart for uveitic macular edema.